Ipsen and Origami Therapeutics, a biotech company developing small-molecule protein degraders and conformation correctors, announced a global collaboration and option agreement on January 30th, 2026. According to a company press release, the goal of the collaboration is to develop a small-molecule protein degrader program targeting a rare, inherited neurodegenerative disorder.

According to the release, Ipsen has obtained an exclusive option to license the program globally following successful drug candidate nomination. Should they exercise it, Ipsen would assume responsibility for global development and commercialization. While Origami is eligible for various upfront, milestone, and royalty payments pursuant to their work in the collaboration, specific financial considerations were not disclosed in the announcement.

“We are delighted to join forces with Origami whose pioneering work in developing protein degraders targeting genetic neurodegenerative diseases represents a powerful new frontier in rare neuroscience,” said Steve Glyman, SVP and Head of Neuroscience Research & Development, Ipsen, in the release. “Their approach aligns seamlessly with Ipsen’s strong rare neuroscience heritage and expertise in small‑molecule innovation, enabling us to advance first‑ and best‑in‑class therapies for people living with debilitating conditions where treatment options remain limited.”

“This collaboration with Ipsen is a strong validation of Origami’s science and of the potential of targeted protein degradation to address the root causes of rare genetic neurodegenerative diseases,” said Beth Hoffman, Ph.D., CEO and Founder, Origami Therapeutics, in the release. “Ipsen brings deep expertise in rare neuroscience and global development, making them an ideal partner as we advance this program toward the clinic. Together, we share a commitment to translating cutting-edge biology into meaningful therapies for patients who currently have limited or no treatment options.”